Radiofrequency ablation represents 34.5% within the technology segment, benign prostatic hyperplasia accounts for 35.8% of the application category and hospitals hold 53.4% of end user demand in 2026. The urology ablation devices market was valued at USD 887.3 million in 2025 and is forecast to post an 8.9% CAGR between 2026 and 2036.